CERO THERAPEUTICS HOLDINGS, INC.

CERO · OTC · SIC 2836: Biological Products, (No Diagnostic Substances)
119
SEC Filings
$0.02
Close 2026-05-21

Business Summary

CERo Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing chimeric engulfment receptor (CER) T-cell therapies for cancer. Its lead product candidate, CER-1236, is being developed as a cell therapy. The company completed a business combination with Phoenix Biotech Acquisition Corp. (PBAX) in February 2024 and is advancing CER-1236 through preclinical studies and clinical trials targeting oncology indications.

Latest Stock Quote

CERO 2026-05-21 $0.02 O:$0.02 H:$0.02 L:$0.0181 Vol:0.7M VWAP:$0.01921
origin leaf: 0704c63c74211848abbd7473a86f6487e421c62a280f9f745d2b92c8186731db

Next Earnings

Q2 FY2026 — expected 2026-09-11

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-04-152024-12-310001213900-25-032134EDGAR110K words
2024-04-022023-12-310001213900-24-029051EDGAR
2023-03-242022-12-310001193125-23-078172EDGAR
2022-03-242021-12-310001193125-22-083868EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-192025-09-300001213900-25-112619EDGAR56K words
2025-08-222025-06-300001213900-25-079898EDGAR
2025-05-152025-03-310001213900-25-044335EDGAR
2024-11-192024-09-300001213900-24-100245EDGAR
2024-08-142024-06-300001213900-24-069055EDGAR
2024-05-172024-03-310001213900-24-044805EDGAR
2023-11-092023-09-300001213900-23-085200EDGAR
2023-08-142023-06-300001213900-23-066987EDGAR
2023-05-122023-03-310001193125-23-143454EDGAR
2022-11-102022-09-300001193125-22-282566EDGAR
2022-08-112022-06-300001193125-22-218504EDGAR
2022-05-132022-03-310001193125-22-150082EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-110001213900-26-025817EDGAR1K words
2026-02-130001213900-26-016474EDGAR
2026-02-040001213900-26-011844EDGAR
2026-02-030001213900-26-011587EDGAR
2026-01-070001213900-26-002187EDGAR
2025-12-190001213900-25-123912EDGAR
2025-12-020001213900-25-116971EDGAR
2025-10-300001213900-25-103661EDGAR
2025-10-160001213900-25-099560EDGAR
2025-10-140001213900-25-098421EDGAR

119 total filings indexed. 93 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

oncology cell-therapy

Company Identity

CIK0001870404
TickerCERO
ExchangeOTC
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 7667d1acb1bc227279ec8d12161a762a5b93bf08d78f02705f619a0f7323ee78
parent: 50342d9ac659cd7d302b3a07cfe2fdf75988bcaad499338b77fd9da961663471
content hash: 5f23bc0d323396e00361332d61e1a2ade446ff16390fe4e8c65f9e5b82971d51
signed: 2026-06-02T19:00:37.100Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf